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Non-small Cell Lung Cancer
Michael T. Vest, DO,* Lynn Tanoue, MD,* Pamela R. Soulos, MPH,† Anthony W. Kim, MD,‡
Frank Detterbeck, MD,‡ Daniel Morgensztern, MD,§ and Cary P. Gross, MD†
Introduction: Guidelines recommend that patients with clinical
stage IIIA non-small cell lung cancer (NSCLC) undergo histologic
confirmation of pathologic lymph nodes. Studies have suggested that
invasive mediastinal staging is underutilized, although practice pat-
terns have not been rigorously evaluated.
Methods: We used the Surveillance, Epidemiology, and End Re-
sults-Medicare database to identify patients with stage IIIA NSCLC
diagnosed from 1998 through 2005. Invasive staging and use of
positron emission tomography (PET) scanning were assessed using
Medicare claims. Multivariable logistic regression was used to identify
patient characteristics associated with use of invasive staging.
Results: Of 7583 stage IIIA NSCLC patients, 1678 (22%) under-
went invasive staging. Patients who received curative intent cancer
treatment were more likely to undergo invasive staging than patients
who did not receive cancer-specific therapy (30% versus 9.8%,
adjusted odds ratio, 3.31; 95% confidence interval, 2.78–3.95). The
oldest patients (age, 85–94 years) were less likely to receive invasive
staging than the youngest (age, 67–69 years; 27.6% versus 11.9%;
odds ratio, 0.46; 95% confidence interval, 0.34–0.61). Sex, marital
status, income, and race were not associated with the use of the
invasive staging. The use of invasive staging was stable throughout
the study period, despite an increase in the use of PET scanning from
less than 10% of patients before 2000 to almost 70% in 2005.
Conclusion: Nearly 80% of Medicare beneficiaries with stage IIIA
NSCLC do not receive guideline adherent mediastinal staging; this
failure cannot be entirely explained by patient factors or a reliance
on PET imaging. Incentives to encourage use of invasive staging
may improve care.
Key Words: Non-small cell lung cancer, Mediastinal staging,
Mediastinoscopy.
(J Thorac Oncol. 2012;7: 188–195)
Accurate staging of lung cancer is essential to the determi-nation of appropriate treatment. Stage IIIA non-small cell
lung cancer (NSCLC) is most commonly defined by cancer
spread to ipsilateral mediastinal (N2) lymph nodes. Prior
studies have indicated that CT and PET scanning lack suffi-
cient sensitivity or specificity to serve as the sole staging
modality.1–10 A 1997 statement from the American Thoracic
Society/European Respiratory Society statement noted that
invasive staging of enlarged lymph nodes is mandatory.11 The
American Thoracic Society, European Respiratory Society, and
American College of Chest Physicians have for many years
endorsed invasive sampling of mediastinal lymph nodes sus-
pected of containing malignant cells.1,11–13 Therefore, patients
should not be given the diagnosis of clinical stage IIIA NSCLC
based on PET scan findings without tissue confirmation.
Prior work has suggested that use of mediastinal stag-
ing is far lower than recommended by guidelines.14–16 One
analysis of trends in staging of Medicare patients diagnosed
with NSCLC between 1998 and 2002 found that 65% of stage
IIIA patients were staged with CT scan only; 30% with CT in
addition to either PET or invasive biopsy; and 5% with CT,
PET, and invasive biopsy.17 This analysis also found a
positive association between use of additional staging modal-
ities and survival.
We examined the actual practice for mediastinal stag-
ing of Medicare patients with stage IIIA NSCLC to explore
the reasons for its underutilization. The advantages of study-
ing the Medicare population include ethnic, socioeconomic,
and geographic diversity and a stable single payer insurance
coverage for the entire period of study. We identified which
staging modalities were most frequently used during the years
1998 to 2005 and examined patient factors associated with
the use of invasive staging.
METHODS
Data Source and Study Sample
This study was deemed exempt by the Yale Human
Investigations Committee. Data were obtained from the Sur-
veillance, Epidemiology, and End Results (SEER)-Medicare
linked database, which contains tumor registry data linked to
Medicare claims for patients representing 26% of the US
population.18,19 Before 2000, only 11 of the current 16 reg-
istries participated in the SEER program; this subset of
registries, which represented 14% of the population, is re-
ferred to in this study as the preexpansion registries.
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We selected subjects aged 67 to 94 years who were
diagnosed with stage IIIA NSCLC between 1998 and 2005.
Patients were identified as IIIA using the American Joint
Committee on Cancer stage variable before 2004 or collab-
orative stage variable after 2004 provided by SEER. The
collaborative stage variable uses all data available from both
clinical staging techniques and surgical resection if per-
formed. Exclusion criteria included the following: unknown
month of diagnosis, diagnosis reported on death certificate or
autopsy, prior lung cancer diagnosis, or any other cancer
diagnosis in the 6 months before and after the stage IIIA
NSCLC diagnosis. To ensure that we had complete data for the
sample, patients had to have been continuously enrolled in
fee-for-service Medicare Parts A and B beginning 24 months
before diagnosis through the earliest of the following events:
initiation of treatment, death, or 6 months after diagnosis.
We also analyzed a subgroup of stage IIIA patients treated
with both chemotherapy and radiation but not surgery within 6
months of diagnosis. This analysis allowed us to confirm our
findings in a group of patients healthy enough for aggressive
treatment and without the impact of unsuspected N2 disease
found incidentally at the time of surgical resection.
Treatment Groups
Treatment was assessed using Medicare claims in the 6
months after diagnosis (Appendix Table A1). We divided
patients into three groups: patients who did not receive
chemotherapy, surgery, or radiation were classified as best
supportive care; patients who received chemotherapy or ra-
diation alone were classified as cancer-specific therapy; and
patients who received combination chemotherapy and radia-
tion therapy or any therapy that involved surgical resection
were classified as curative intent therapy.
Outcome
The primary outcome was receipt of invasive medias-
tinal staging. We used the inpatient, outpatient, and physician
Medicare claims to search for current procedural terminology
(CPT) codes for PET scan, mediastinoscopy, mediastinot-
omy, transbronchial needle aspiration (TBNA), endoscopic
ultrasound (EUS), or video-assisted thoracoscopic surgery
biopsies (Appendix Table A1). For the majority of the study
period, endobronchial ultrasound (EBUS)-TBNA and con-
ventional TBNA were billed using the same CPT code, hence
we could not separate these two procedures. For analytic pur-
poses, we combined mediastinoscopy and mediastinotomy into
one group. We searched for mediastinal staging procedures
performed 6 months before diagnosis through the initiation of
treatment or for 6 months after diagnosis in the case of patients
who were not treated with any cancer-specific therapy.
As a secondary outcome, we calculated the 3-year sur-
vival of the subset of stage IIIA NSCLC patients who were
diagnosed in 1998 to 2004 and received both chemotherapy and
radiation within 6 months of diagnosis but did not undergo surgery.
Covariates
The following variables were selected a priori as factors
that might influence whether a patient received invasive
staging: age, sex, race, comorbidities, marital status, income,
health care system access, treatment group as defined above,
SEER registry, and year of diagnosis. Age was categorized as
67–69, 70–74, 75–79, 80–84, and 85 years and older; race as
white, black, or other; and marital status as married, unmar-
ried, or unknown. Income was defined as the median house-
hold income at the zip code level categorized into quintiles.
We created a dichotomous variable indicating whether a
claim had been submitted for influenza vaccination in the 18
months before the diagnosis, which has been used previously
as marker for health care system access.20
Comorbidity was assessed by searching all Medicare
claims in the 2 years before diagnosis. We used the comorbid
conditions recommended by Elixhauser et al.21 which were
previously determined to be significantly associated with sur-
vival (Appendix Table A2). Only codes that appeared on at least
one inpatient claim or two or more outpatient/physician claims
occurring more than 30 days apart were used. We created a sum
score of the number of comorbidities each patient had and then
stratified patients into three groups: 0, 1 to 2, or3 comorbidities.
Statistical Analysis
We determined the percent of patients receiving each
type of invasive staging procedure for each year during the
study period (1998–2005). Bivariate and multivariate logistic
regression was used to identify patient factors associated with
receipt of invasive staging. For the secondary analysis, we
conducted a logistic regression analysis using 3-year survival
as the outcome. SAS statistical software, version 9.2 (SAS
Institute Inc., Cary, NC), was used for all analysis.
RESULTS
Our sample consisted of 7583 patients (Table 1). Of the
7583 patients, 1678 (22%) underwent at least one invasive
staging procedure. Of these, 88% received a single invasive
staging procedure such as mediastinoscopy alone, while 12%
received two or more invasive staging procedure such as
TBNA followed by mediastinoscopy.
As shown in Figure 1, mediastinoscopy (or mediastinot-
omy) was the most commonly used invasive procedure (76% of
invasively staged patients) followed by TBNA with or without
ultrasound guidance (26% of invasively staged patients). Video-
assisted thoracoscopic surgery and EUS were rarely used.
The use of invasive staging did not change significantly
during the study period. Nevertheless, the use of PET scanning
increased from 2.4% in 1998 to 68.4% in 2005 (Figure 2).
In the unadjusted analysis, older age, black race, higher
comorbidity, or being unmarried significantly decreased the
likelihood of receiving invasive staging (Table 2). Patients who
received aggressive cancer treatment were significantly more
likely to have received invasive staging. Nevertheless, even
among these patients, only a minority (30%) underwent invasive
staging. Furthermore, even in the “high likelihood” subgroups
(no comorbidities, white, and married) less than 30% underwent
invasive staging.
After adjusting for all significant variables, only age,
comorbidity, receipt of influenza vaccination, and treatment
type remained independently associated with use of invasive
staging. Patients with 3 comorbidities were less likely to
have received invasive staging compared with patients with-
Journal of Thoracic Oncology • Volume 7, Number 1, January 2012 Mediastinal Staging in Stage IIIA NSCLC
Copyright © 2011 by the International Association for the Study of Lung Cancer 189
out any comorbidity (odds ratio, 0.81; 95% confidence inter-
val [CI], 0.69–0.95), while patients who had greater health
care access, as measured by receipt of influenza vaccination,
were more likely to have received invasive staging compared
with patients who did not receive the vaccine (odds ratio,
1.23; 95% CI, 1.09–1.39). Nevertheless, in all subgroups, the
use of invasive staging was the exception rather than the rule.
There was significant geographic variation in the use of
invasive staging between SEER registry (Tables 2 and 3).
Receipt of cancer-specific therapy and curative intent
therapy were associated with use of invasive staging. Never-
theless, even in the subset of patients who received combined
radiation therapy and chemotherapy, only 30% underwent
invasive staging. Only age, SEER registry, and receipt of
influenza vaccination were significant covariates (Table 3).
In patients treated with both chemotherapy and radiation
but not surgical resection, 3-year survival was 21%. In multi-
variate analysis of this group, invasive staging was associated
with improved 3-year survival (adjusted hazard ratio, 1.61; 95%
CI, 1.21–2.12). Other factors associated positively with survival
included younger age and fewer comorbidities (Table 4).
DISCUSSION
We found an underutilization of histologic confirma-
tion in clinical staging during the years 1998 to 2005. This
practice was inconsistent with evidence-based guidelines.
The failure of physicians to follow clinical practice guidelines
is well documented across different specialties. A review by
Cabana et al.22 described reasons that guidelines are not
followed which are discussed below.
TABLE 1. Baseline Characteristics of Cohort and Use of
Invasive Staging Techniques in Stage IIIA NSCLC, N  7583
n (%)
Age (yr)
67–69 1118 (15)
70–74 2305 (30)
75–79 2197 (29)
80–84 1331 (18)
85–94 632 (8)
Sex
Male 4308 (57)
Female 3275 (43)
Race
White 6653 (88)
Black 635 (8)
Other 295 (4)
Marital status
Married 3972 (52)
Unmarried 3349 (44)
Unknown 262 (4)
Income
First quintile 1449 (19)
Second quintile 1451 (19)
Third quintile 1446 (19)
Fourth quintile 1450 (19)
Fifth quintile 1447 (19)
Unknown 340 (4)
Influenza vaccination in previous 18 mo
No 4013 (53)
Yes 3570 (47)
Treatment groupa
Best supportive care 1834 (24)
Cancer-specific therapy 2051 (27)
Curative intent therapy 3698 (49)
Receipt of invasive staging
No 1678 (22)
Yes 5905 (78)
a Patients classified as best supportive care did not receive any cancer-specific
therapy (chemotherapy, radiation, or surgery). Patients who received chemotherapy or
radiation alone were classified as cancer-specific therapy. Patients who received com-
bination chemotherapy and radiation therapy or any therapy that involved surgical
resection were classified as curative intent therapy.
NSCLC, non-small cell lung cancer.
FIGURE 1. Invasive staging techniques. In all, 1678 patients
underwent invasive staging. Mediastinoscopy/mediastinotomy
was used in 1270 patients (76%), transbronchial needle aspira-
tion in 451 (26%), video-assisted thoracic surgery in 35 (2%),
and esophageal ultrasound in 28 (1.6%). Because 12.5% of
invasively staged patients underwent more than one proce-
dure, the numbers sum to more than 100%.
FIGURE 2. Use of PET (positron emission tomography)
scanning and invasive staging, 1998 to 2005, in preexpan-
sion registries.
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Physicians might be unaware of evidence supporting
recommendations for invasive staging in IIIA lung cancer
patients. The extensive evidence base supporting the guide-
lines and the lack of an obvious change after publication of
the American College of Chest Physician guidelines in 2003
suggest that this is not the case.
Clinicians might disagree with guidelines even at a
population level. This seems unlikely given the lack of debate
in the literature regarding the value of staging IIIA NSCLC.
Nevertheless, diagnostic and therapeutic nihilism related to
the perception that little can be done for patients with lung
cancer may be pertinent.23,24
Clinicians might agree with guidelines on a population
level but feel they were not relevant to an individual patient. For
example, a physician might believe that the positive predictive
value of CT and PET in an individual patient is sufficiently
reliable to obviate the need for histologic confirmation while
acknowledging that this position is not supported by evidence.
Many clinicians may not feel confident in their ability to perform
invasive staging techniques specified by guidelines. This may
subconsciously increase the likelihood of a physician recom-
mending guideline discordant care for a particular patient.
Limited access to invasive staging procedures may dis-
courage adherence to guidelines. Only approximately 12% of
pulmonologists perform TBNA25–27 and less than 10% of lung
cancer surgery is performed by dedicated thoracic surgeons.28
General surgeons or cardiac surgeons performing thoracic sur-
gery are less likely to truly be comfortable with mediastinos-
copy. Nevertheless, shifting all NSCLC care to specialized
expertise is anything but simple. Even if all NSCLC cancer
treatment was centralized at large centers, it is not clear if there
are sufficient physicians trained to meet the needs of this large
group of patients. Moreover, in the United States, such central-
ization would require a major cultural shift and many elderly
patients would likely be unwilling to travel for this care.
TABLE 2. Unadjusted and Adjusted Odds Ratios for Receipt
of Invasive Staging
N
(% Staged)
Unadjusted Adjusted
OR 95% CI OR 95% CI
Age group
67–69 1118 (27.6) 1.00 — 1.00 —
70–74 2305 (25.4) 0.90 0.76–1.05 0.92 0.78–1.09
75–79 2197 (22.4) 0.76 0.64–0.90 0.81 0.68–0.96
80–84 1331 (16.3) 0.51 0.42–0.62 0.57 0.46–0.70
85–94 632 (11.9) 0.35 0.27–0.47 0.46 0.34–0.61
Sex
Male 4308 (22.1) 1.00 — n/a
Female 3275 (22.2) 1.01 0.91–1.13 n/a
Race
White 6653 (22.5) 1.00 — 1.00 —
Black 635 (17.3) 0.72 0.58–0.89 0.88 0.69–1.12
Other 295 (24.4) 1.11 0.85–1.46 1.33 0.97–1.83
Comorbidities
0 2747 (24.1) 1.00 — 1.00 —
1–2 3169 (22.6) 0.92 0.82–1.04 0.93 0.82–1.05
3 1667 (18.1) 0.70 0.60–0.81 0.81 0.69–0.95
Marital status
Married 3972 (24.3) 1.00 — 1.00 —
Unmarried 3349 (19.7) 0.82 0.72–0.92 0.93 0.83–1.05
Unknown 262 (19.9) 0.78 0.55–1.10 1.01 0.73–1.40
Income
First quintile 1449 (17.7) 1.00 — 1.00 —
Second quintile 1451 (21.4) 1.26 1.05–1.52 1.07 0.87–1.30
Third quintile 1446 (22.4) 1.34 1.12–1.61 0.99 0.81–1.22
Fourth quintile 1450 (24.3) 1.49 1.24–1.78 1.09 0.88–1.34
Fifth quintile 1447 (24.9) 1.54 1.28–1.84 1.12 0.90–1.39
Unknown 340 (22.1) 1.31 0.98–1.75 1.13 0.83–1.54
Influenza vaccination
in previous 18 mo
No 3570 (19.7) 1.00 — 1.00 —
Yes 4013 (24.3) 1.31 1.17–1.46 1.23 1.09–1.39
Year of diagnosis
1998 502 (22.7) 1.00 — n/a
1999 461 (24.3) 1.09 0.81–1.47 n/a
2000 1033 (22.6) 0.99 0.77–1.28 n/a
2001 983 (19.8) 0.84 0.65–1.09 n/a
2002 1038 (8.8) 0.79 0.61–1.02 n/a
2003 1130 (21.2) 0.92 0.71–1.18 n/a
2004 1247 (23.7) 1.06 0.83–1.36 n/a
2005 1189 (24.6) 1.11 0.87–1.43 n/a
Treatment group
Best supportive
care
1834 (9.8) 1.00 — 1.00 —
Cancer-specific
therapy
2051 (19.1) 2.18 1.80–2.63 2.18 1.80–2.66
Curative intent
therapy
3698 (30.0) 3.96 3.34–4.69 3.31 2.78–3.95
SEER registry
San Francisco 253 (13.8) 1.00 — 1.00 —
Connecticut 558 (26.5) 2.25 1.50–3.37 2.07 1.36–3.14
Detroit 866 (25.5) 2.13 1.45–3.15 2.04 1.36–3.06
Hawaii 131 (13.7) 0.99 0.54–1.83 0.68 0.35–1.30
N
(% Staged)
Unadjusted Adjusted
OR 95% CI OR 95% CI
Iowa 602 (24.6) 2.03 1.36–3.04 1.87 1.21–2.88
New Mexico 140 (17.1) 1.29 0.73–2.27 1.29 0.71–2.34
Seattle 486 (32.5) 3.00 2.00–4.50 3.05 1.99–4.66
Utah 94 (22.3) 1.79 0.98–3.27 1.69 0.91–3.17
Atlanta 258 (21.3) 1.69 1.06–2.69 1.55 0.96–2.50
San Jose 153 (20.3) 1.58 0.93–2.69 1.33 0.77–2.30
Los Angeles 496 (30.0) 2.68 1.78–4.01 2.48 1.63–3.78
Rural Georgia a 0.86 0.29–2.59 0.91 0.29–2.80
Greater California 1181 (20.1) 1.56 1.07–2.30 1.51 1.01–2.26
Kentucky 840 (15.5) 1.14 0.76–1.71 1.05 0.69–1.63
Louisiana 562 (15.1) 1.11 0.73–1.70 1.14 0.72–1.79
New Jersey 930 (23.0) 1.86 1.26–2.75 1.70 1.13–2.54
Best supportive care, not treated with surgery, chemo, or radiation; cancer-specific
therapy, treated with chemotherapy or radiation alone; curative intent therapy, treated
with combination chemotherapy and radiation or any combination that included surgical
resection; N, number of patients; %staged, percent of patients who underwent invasive
clinical staging; Adjusted OR, adjusted odds ratio adjusted for age, race, SEER region,
comorbidities, income, and access to health care services as measured by receipt of
influenza vaccination.
a Suppressed to protect confidentiality because of cell size.
OR, odds ratio; CI, confidence interval.
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TABLE 3. Multivariable Analysis to Predict Use of Invasive
Staging Among Subset of Stage IIIA Patients Treated with
Combined Chemotherapy and Radiation
Variable
Unadjusted Adjusted
Odds Ratio 95% CI Odds Ratio 95% CI
Age
67–69 1.00 —
70–74 0.85 0.66–1.12 0.80 0.61–1.04
75–79 0.63 0.47–0.83 0.58 0.43–0.77
80–84 0.47 0.33–0.67 0.27 027–0.57
85–94 0.41 0.21–0.80 0.36 0.18–0.71
Sex
Male 1.00 85–94
Female 1.18 0.97–1.43 Not significant Not significant
Race
White 1.00
Black 0.72 0.49–1.06
Other 1.68 1.02–2.78
Comorbidities
0 1.00
1–2 1.00 0.81–1.24
3 0.80 0.60–1.06
Marital status
Married 1.00
Unmarried 0.98 0.80–1.20 Not significant Not significant
Unknown 1.13 0.65–1.95 Not significant Not significant
Income
First quintile 1.00 n/a n/a
Second quintile 1.37 1.00–1.89 1.30 0.92–1.84
Third quintile 1.32 0.96–1.83 1.06 0.74–1.52
Fourth quintile 1.45 1.05–2.00 1.11 076–1.61
Fifth quintile 1.58 1.14–2.18 1.28 0.86–1.88
Unknown 1.14 0.67–1.94 0.86 0.49–1.52
Influenza vaccination
in previous
18 mo
No 1.00 n/a n/a
Yes 1.28 1.05–1.56 1.31 1.06–1.61
Year of diagnosis
1998 1.00
1999 1.03 0.58–1.84
2000 1.04 0.64–1.70
2001 0.62 0.37–1.05
2002 0.67 0.40–1.10
2003 0.75 0.46–1.22
2004 1.07 0.67–1.70
2005 0.97 0.61–1.55
SEER registry
San Francisco 1.00
Connecticut 3.72 1.46–9.34 4.57 1.74–12.01
Detroit 4.18 1.71–10.20 5.46 2.15–13.86
Hawaii 1.19 0.31–4.65 0.64 0.15–2.68
Iowa 3.71 1.49–9.24 4.33 1.65–11.38
New Mexico 2.63 0.88–7.88 3.31 1.05–10.40
Seattle 5.53 2.21–13.84 6.52 2.51–16.92
Utah 2.87 0.80–10.26 3.07 0.83–11.44
Atlanta 3.18 1.20–8.49 4.19 1.52–11.58
San Jose 2.24 0.74–6.80 2.51 0.81–7.80
Los Angeles 5.47 2.13–14.06 6.82 2.57–18.10
Rural Georgia 1.02 0.11–9.84 1.71 0.17–16.94
Greater California 2.26 0.93–5.51 2.71 1.07–6.86
Kentucky 2.03 0.81–5.06 2.43 0.93–6.38
Louisiana 2.14 0.84–5.42 2.78 1.04–7.43
New Jersey 2.90 1.18–7.09 3.58 1.42–9.06
OR, odds ratio; CI, confidence interval; n/a, not applicable.
TABLE 4. Results of Multivariable Analysis to Predict 3-yr
Survival for Patients Treated with Chemotherapy and
Radiationa
Variable
Unadjusted Adjusted
Odds Ratio 95% CI Odd Ratio 95% CI
Age
67–69 1.00 n/a n/a
70–74 0.60 0.42–0.85 0.61 0.43–0.90
75–79 0.70 0.49–0.99 0.75 0.52–1.08
80–84 0.47 0.30–0.75 0.533 0.33–0.86
85–99 0.22 0.07–0.73 0.26 0.08–0.86
Sex
Male 1.00 85–99 n/a n/a
Female 1.57 1.21–2.03 1.52 1.17–1.99
Race
White 1.00 n/a n/a
Black 0.98 0.60–1.6 1.18 0.70–2.0
Other 0.93 0.43–2.00 0.85 0.39–1.85
Comorbidities
0 1.00 n/a n/a
1–2 0.96 0.73–1.27 1.02 0.77–1.35
3 0.43 0.27–0.68 0.49 0.31–0.78
Marital status
Married 1.00 n/a n/a n/a
Unmarried 0.86 0.65–1.3
Unknown 0.75 0.33–1.68
Income
First quintile 1.00 n/a n/a
Second quintile 1.21 0.72–1.74 1.11 0.71–1.75
Third quintile 1.20 0.78–1.86 1.21 0.76–1.91
Fourth quintile 1.54 1.01—-2.35 1.51 0.97–2.37
Fifth quintile 1.42 0.92–2.18 1.41 0.89–2.34
Unknown 0.78 0.33–1.82 0.83 0.35–1.97
Influenza vaccination
in previous
18 mo
No 1.00
Yes 1.21 0.86–1.46
Year of diagnosis
1998 1.00
1999 1.31 0.6–2.85
2000 1.01 0.51–2.01
2001 1.53 0.58–2.30
2002 1.59 0.82–3.08
2003 1.49 0.78–2.87
2004 1.81 0.96–3.41
SEER registry
San Francisco 1.00
Connecticut 2.26 0.72–7.08
Detroit 2.55 0.86–7.55
Hawaii 2.00 0.45–9.00
Iowa 2.11 0.69–6.43
New Mexico 0.85 0.18–4.11
Seattle 2.06 0.66–6.38
Utah 2.27 0.50–10.29
Atlanta 1.47 0.43–5.04
San Jose 1.76 0.45–6.84
Los Angeles 2.33 0.73–7.49
Rural Georgia 1.70 0.16–18.44
Greater California 1.52 0.51–4.54
Kentucky 1.45 0.47–4.43
Louisiana 1.13 0.35–3.63
New Jersey 1.38 0.45–4.18
OR, odds ratio; CI, confidence interval, n/a, not applicable.
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These data suggest that some physicians routinely per-
formed invasive staging and did so throughout the study period,
while another larger group routinely did not. Simply publishing
guidelines and evidence supporting them is not sufficient to
change practice. The rate of invasive staging is likely to reflect
the availability of physicians with the skills and training to
routinely perform invasive mediastinal staging. To actually im-
prove patient care, leaders need to ensure that physicians have
the resources needed to provide the recommended care and that
incentives are aligned to encourage best practices.
Training physicians who currently care for lung cancer
patients in invasive staging techniques and providing institu-
tional resources for them may be the key to achieving
guideline adherent care. For example, both practicing pul-
monologists and practicing surgeons have successfully ad-
opted EBUS-TBNA.29 Nevertheless, the process of becoming
an expert in a new procedure is arduous and the profession’s
experience with the introduction of laparoscopy taught us to
be cautious.30 Medical simulation is expensive but can reduce
the learning curve for a new procedure and has been used in
thoracic surgery.31 Even after use of simulation training, many
physicians still want mentoring during their initial procedures.
Unfortunately, there are many regulatory barriers to obtaining
this mentoring including lack of reciprocity for licensing and
credentialing. Addressing the need for effective continuing med-
ical education should be a priority for medical leaders who
desire to increase the rate of invasive staging of NSCLC.
Physicians and institutions also need incentives to pur-
sue the difficult and expensive process of safely introducing
invasive staging into their lung cancer practices. One policy-
based approach that may be effective is using the rate of
invasive staging as quality indicator for the care of lung cancer
patients. The recent past has shown us examples of how selec-
tion of quality indicators can dramatically impact practice in
areas such as management of myocardial infarction.
The rate of use of invasive staging was not impacted by
the increased use of PET. This shows that at least in stage
IIIA patients, PET was not replacing invasive staging, be-
cause this would have led to a decrease in invasive staging.
Moreover, identification of PET avid lymph nodes did not
prompt invasive staging for confirmation as recommended by
guidelines because an increase in invasive would have ac-
companied this later scenario. This again suggests that guide-
lines alone are insufficient to change practice.
Our analysis is consistent with and expands on previous
work.17 By separating patients invasively staged from those
staged with a combination of CT scan and PET, we can
appreciate how actual practice is differing from guidelines
and expert opinion. We noted even higher rates of utilization
of PET scanning than reported by Farjah et al.17 This may be
due to our inclusion of additional CPT codes for PET scan-
ning not used in their study and our extended study period. In
addition, we did not observe the decline in utilization of
invasive staging procedures that they reported. This is likely
related to our inclusion of TBNA as an invasive staging
procedure and our focus on patients with stage IIIA NSCLC
who may be more likely to receive invasive staging than
patients with either earlier or more advanced stages.
Our study has several limitations. First, data are only
available on patients diagnosed through 2005. The impact of
the dissemination of technologies such as EBUS and EUS
over the last 5 years cannot be assessed. Second, we specif-
ically evaluated an older Medicare population, and the results
may not be generalizable to younger patients with other
insurance. Nevertheless, while age and insurance status are
known to impact cancer therapies, most lung cancer patients
are older than 65 years. Third, the use of SEER registry to
examine geographic variability does not reflect geographic
distribution of health care resources. Nevertheless, our point
in including this variation is only to provide additional
evidence that variability in the use of staging techniques is
due to factors other than patient characteristics. Furthermore,
because patients may have diagnostic and treatment proce-
dures at multiple institutions, assigning the responsibility for
their care to single institution for research purposes is diffi-
cult. Therefore, we do not have data on the providers that
treated any particular patient. Fourth, the SEER-Medicare
database does not allow the determination of the results of an
individual staging procedure in any given patient. In addition,
we are subject to the limitations of using an administrative
database. For example, if a TBNA were to be performed but
not billed, we would classify the patient incorrectly as not
having had a TBNA. Nevertheless, because this billing data-
base is how providers are reimbursed, we are likely to capture
the majority of procedures. The presence of patients in whom
the absence of invasive staging would be considered medi-
cally acceptable is a potential confounder in our study.
Some patients may have been classified as IIIA in the
SEER database but were only found postoperatively to have N2
involvement (incidental N2). Nevertheless, one can argue these
patients should have had invasive staging to prevent this situa-
tion, and studies indicate the rate of incidental N2 should be
small. Another group for whom invasive staging can be ques-
tioned is those with mediastinal infiltration of tumor to the extent
that individual nodes can no longer be discerned. Nevertheless,
in clinical practice, this group would clearly be a minority of
patients with stage IIIA disease. Finally, comorbidities may
preclude considering curative intent treatment. Data from this
study suggest that more than 36% had no comorbidities.
In the end, the lack of invasive staging cannot be ex-
plained away as having been appropriate because of tumor
extent or comorbidities. Even in the most favorable subgroups
and youngest patients without comorbidities, the rate of invasive
staging was remarkably low (30%). Furthermore, our analyses
excluding surgical patients (and thus any incidental N2 patients)
did not affect the results. Although the exact rate of invasive
staging that should be performed cannot be determined, there is
little doubt it should be substantially higher than less than 25%.
CONCLUSION
The majority of patients with stage IIIA NSCLC did not
receive invasive mediastinal staging as recommended by guide-
lines and associated with improved survival. This was evident
for patients of all races and socioeconomic strata. Patient-related
factors such as age and comorbidity do not fully explain this
practice variation. This combined with the observed geographic
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variation in rates of invasive staging suggest that provider, not
patient, factors are responsible. Incentives to encourage use of
invasive staging may be useful in improving quality of care.
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APPENDIX
TABLE A1. Codes for Identification of Staging Techniques
and Treatments
HCPCS codes for
invasive staging
techniques
Endobronchial ultrasound 31620
Bronchoscopy with TBNA 31629, 31633, 32605
Thoracoscopy of mediastinal
space without biopsy
32605
VATS mediastinal biopsy 32606
Mediastinotomy 39000, 39010
Mediastinoscopy 39400
Esophageal ultrasound 43231, 43242, 43259,
76975
Esophageal ultrasound
guided aspiration
43232
HCPCS codes for
surgical
resection
Carinal reconstruction
Open pneumonectomy 32440
Removal of lung, total
pneumonectomy; with
resection of segment of
trachea followed by
bronchotracheal
anastomosis (sleeve
pneumonectomy)
32442
Removal of lung, total
pneumonectomy;
extrapleural
32445
Open lobectomy 32480
Open bilobectomy 32482
Open segmentectomy 32484
Open sleeve lobectomy 32486
Open completion
pneumonectomy
32488
Open apical resection 32503
Resection of lung; with
resection of chest wall
32520
Resection of lung; with
reconstruction of chest
wall, without prosthesis
32522
Resection of lung; with
major reconstruction of
chest wall, with prosthesis
32525
VATS segmentectomy/
lobectomy
32663
HCPCS codes for
radiation
treatment
Brachytherapy 77750–77799, 0182T
Any external beam (3D
conformal)
77402–416
Any IMRT (77301 and 77427),
77418, 0073T,
G0174
Stereotactic surgery
(radiosurgery/cyberknife)
G0173, G0242, G0243,
G0251, G0338,
G0339, G0340,
0082T-0083T
Any proton beam 77520–77525
Any IGRT 77421
HCPCS codes for
PET scan
G codes G0211, G0212, G0125,
G0126, G0210,
G0212, G0234
CPT codes 78811, 78812, 78813,
78815, 78816
Codes for
chemotherapy
treatment (any
chemo drug)
HCPCS 96400–96549, Q0083-
Q0085, J9000-J9999,
G0355–62
ICD9 V58.1
TBNA, transbronchial needle aspiration; VATS, video-assisted thoracoscopic
surgery; IMRT, intensity-modulated radiation therapy; IGRT, image guided radia-
tion therapy; HCPCS, Healthcare Common Procedure Coding System; PET, posi-
tron emission tomography.
TABLE A2. Comorbid Conditions
Comorbid Condition n (%)
Chronic pulmonary disease 2401 (31.66)
Diabetes uncomplicated 1284 (16.93)
Cardiac arrhythmia 1257 (16.58)
Peripheral vascular disorders 1027 (13.54)
Congestive heart failure 978 (12.9)
Solid tumor without metastasis 827 (10.91)
Fluid and electrolyte disorders 592 (7.81)
Valvular disease 503 (6.63
Depression 433 (5.71)
Diabetes complicated 329 (4.34)
Deficiency anemia 294 (3.88)
Rheumatoid arthritis/collagen disease 241 (3.18)
Other neurological disorders 224 (2.95)
Renal failure 202 (2.66)
Weight loss 161 (2.12)
Pulmonary circulation disorders 146 (1.93)
Alcohol abuse 105 (1.38)
Coagulopathy 101 (1.33)
Liver disease 72 (0.95)
Metastatic cancer 72 (0.95)
Psychoses 71 (0.94)
Paralysis 68 (0.9)
Lymphoma 60 (0.79)
Drug abuse 33 (0.44)
AIDS/HIV a
a Suppressed because of small cell size.
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